A phase 1 trial of fenobam, another mGluR5 NAM, showed target engagement with prepulse inhibition in participants with FXS [65], yet subsequent trials failed to show a behavioral benefit across the trial cohort in phase 2a and b trials in adolescents and adults [66,67]. Here, GRM5 is linked to fragile X syndrome.